Genetic polymorphisms as multi-biomarkers in severe acute respiratory syndrome (SARS) by coronavirus infection: A systematic review of candidate gene association studies

Santos, Ana Caroline Melo dos; Santos, Bárbara Rayssa Correia dos; Santos, Bruna Brandão dos; Ferreira, Jean Moisés; Santos, Luana Karen Correia dos; Oliveira, Susana Paiva; Dias, Renise Bastos Farias; Silva, Aline Cristine Pereira e; Farias, Karol Fireman de; Figueiredo, Elaine Virgínia Martins de Souza

doi:10.1016/j.meegid.2021.104846

Cited by 14 publications

(14 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several polymorphic genes were investigated for differences in susceptibility and protection against SARS-CoV-1, which virus has similar structure, RNA sequence, and receptor binding properties to SARS-CoV-2 [ 69 ]. Important human polymorphisms were also reported in HLA , ACE1 , OAS-1 , MxA , PKR , MBL , E-CR1 , FcγRIIA , MBL2 , L-SIGN (CLEC4M) , IFNG , CD14 , ICAM3 , RANTES , IL-12 RB1 , TNFA , CXCL10/IP-10 , CD209 (DC-SIGN) , AHSG , CYP4F3 , and CCL2 [ 69 ].…”

Section: Human Polymorphism May Influence Sars-cov-2 Viral Entry and ...mentioning

confidence: 99%

Viral and Host Genetic and Epigenetic Biomarkers Related to SARS-CoV-2 Cell Entry, Infection Rate, and Disease Severity

Gašperšič

Dolžan

2022

Biology

View full text Add to dashboard Cite

The rapid spread of COVID-19 outbreak lead to a global pandemic declared in March 2020. The common features of corona virus family helped to resolve structural characteristics and entry mechanism of SARS-CoV-2. However, rapid mutagenesis leads to the emergence of new strains that may have different reproduction rates or infectivity and may impact the course and severity of the disease. Host related factors may also play a role in the susceptibility for infection as well as the severity and outcomes of the COVID-19. We have performed a literature and database search to summarize potential viral and host-related genomic and epigenomic biomarkers, such as genetic variability, miRNA, and DNA methylation in the molecular pathway of SARS-CoV-2 entry into the host cell, that may be related to COVID-19 susceptibility and severity. Bioinformatics tools may help to predict the effect of mutations in the spike protein on the binding to the ACE2 receptor and the infectivity of the strain. SARS-CoV-2 may also target several transcription factors and tumour suppressor genes, thus influencing the expression of different host genes and affecting cell signalling. In addition, the virus may interfere with RNA expression in host cells by exploiting endogenous miRNA and its viral RNA. Our analysis showed that numerous human miRNA may form duplexes with different coding and non-coding regions of viral RNA. Polymorphisms in human genes responsible for viral entry and replication, as well as in molecular damage response and inflammatory pathways may also contribute to disease prognosis and outcome. Gene ontology analysis shows that proteins encoded by such polymorphic genes are highly interconnected in regulation of defense response. Thus, virus and host related genetic and epigenetic biomarkers may help to predict the course of the disease and the response to treatment.

show abstract

Section: Human Polymorphism May Influence Sars-cov-2 Viral Entry and ...mentioning

confidence: 99%

Viral and Host Genetic and Epigenetic Biomarkers Related to SARS-CoV-2 Cell Entry, Infection Rate, and Disease Severity

Gašperšič

Dolžan

2022

Biology

View full text Add to dashboard Cite

show abstract

“…On the other hand, mutations of these repair genes seem to drive oncogenesis [38]. In this respect, certain identified genes, including E2F transcription factors and retinoblastoma tumor-suppressor gene (RB1), modulated by COVID-19 infection, appear to be involved in SARS-CoV-2-related carcinogenesis [39]; genetic variants of IL12RB1 confer genetic susceptibility to SARS-CoV-2 infection [40]; and mutations to RB1 and/or components regulating the cyclin dependent kinase-RB-E2F signaling pathway have been recognized in almost every human cancer [41]. In this setting, mutations in genes (hMSHS2, hMLS1, hPMS1, hPMS2) that also control the DNA mismatch repair process have been involved in oncogenesis.…”

Section: Immunity After Sars-cov-2 Infection Versus Post Vaccinationmentioning

confidence: 99%

Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic

et al. 2022

View full text Add to dashboard Cite

The persistence of the coronavirus disease 2019 (COVID-19) pandemic has triggered research into limiting transmission, morbidity and mortality, thus warranting a comprehensive approach to guide balanced healthcare policies with respect to people’s physical and mental health. The mainstay priority during COVID-19 is to achieve widespread immunity, which could be established through natural contact or vaccination. Deep knowledge of the immune response combined with recent specific data indicates the potential inferiority of induced immunity against infection. Moreover, the prevention of transmission has been founded on general non-pharmacological measures of protection, albeit debate exists considering their efficacy and, among other issues, their socio-psychological burden. The second line of defense is engaged after infection and is supported by a plethora of studied agents, such as antibiotics, steroids and non-steroid anti-inflammatory drugs, antiviral medications and other biological agents that have been proposed, though variability in terms of benefits and adverse events has not allowed distinct solutions, albeit certain treatments might have a role in prevention and/or treatment of the disease. This narrative review summarizes the existing literature on the advantages and weaknesses of current COVID-19 management measures, thus underlining the necessity of acting based on the classical principle of “ofeleein i mi vlaptin”, that is, to help or not to harm.

show abstract

“…Subsequently, the 2′–5′-linked oligoadenylates act as second messengers and activate latent ribonuclease (RNAase L) to degrade cellular and viral RNA, whose remnants are then sensed by RLRs [ 186 , 187 , 188 ]. OAS polymorphisms have been seen in patients with severe COVID-19 disease [ 189 , 190 , 191 ]. An OAS-1 polymorphism was also associated with severe cases of SARS-CoV-1 [ 192 ].…”

Section: Interferon-stimulated Genesmentioning

confidence: 99%

The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2

Aliyari

Quanquin

Pernet³

et al. 2022

Pathogens

View full text Add to dashboard Cite

Compared to what we knew at the start of the SARS-CoV-2 global pandemic, our understanding of the interplay between the interferon signaling pathway and SARS-CoV-2 infection has dramatically increased. Innate antiviral strategies range from the direct inhibition of viral components to reprograming the host’s own metabolic pathways to block viral infection. SARS-CoV-2 has also evolved to exploit diverse tactics to overcome immune barriers and successfully infect host cells. Herein, we review the current knowledge of the innate immune signaling pathways triggered by SARS-CoV-2 with a focus on the type I interferon response, as well as the mechanisms by which SARS-CoV-2 impairs those defenses.

show abstract

Genetic polymorphisms as multi-biomarkers in severe acute respiratory syndrome (SARS) by coronavirus infection: A systematic review of candidate gene association studies

Cited by 14 publications

References 127 publications

Viral and Host Genetic and Epigenetic Biomarkers Related to SARS-CoV-2 Cell Entry, Infection Rate, and Disease Severity

Viral and Host Genetic and Epigenetic Biomarkers Related to SARS-CoV-2 Cell Entry, Infection Rate, and Disease Severity

Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic

The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2

Contact Info

Product

Resources

About